Johnson & Johnson (jnj)
JNJ — Company Overview
Investors tracking JNJ follow a Drug Manufacturers - General name listed on NYQ within Healthcare.
| Ticker | JNJ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NYQ |
| Market cap | $648.67B |
| Last price | $269.17 |
| Size category | Mega Cap |
JNJ — Business Description
The business profile of Johnson & Johnson (JNJ) reflects its role in Drug Manufacturers - General. Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals…
Official website: https://www.jnj.com.
JNJ — Investment Thesis
Johnson & Johnson (JNJ) attracts investors weighing Drug Manufacturers - General fundamentals against current market pricing.
- Revenue is expanding at roughly 6.6% year-over-year (public data).
- Trailing P/E of 31.26× sits in a moderate band relative to high-growth peers.
- Forward P/E (22.18×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 2.0% adds an income component to total return.
- Equity market capitalization is approximately $648.67B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
JNJ — Financial Health
JNJ financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin of 21.5% indicates solid bottom-line conversion. Positive free cash flow of $16.89B supports balance-sheet flexibility.
| Trailing P/E | 31.26× |
| Forward P/E | 22.18× |
| Price / Sales | 6.62× |
| Price / Book | 7.63× |
| Gross margin | 68.1% |
| Operating margin | 29.2% |
| Profit margin | 21.5% |
| Return on equity | 25.7% |
| Debt / Equity | 57.71 |
| Free cash flow | $16.89B |
JNJ — Growth Outlook
Growth outlook for Johnson & Johnson (JNJ) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 6.6% suggests steady but measured expansion.
- Earnings declined -0.9% year-over-year — margin or volume pressure may be in play.
- Price is 4.2% below the 52-week high.
JNJ — Competitive Position
Johnson & Johnson (JNJ) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - General.
- Market capitalization of $648.67B places JNJ among mega-cap peers.
- Gross margin near 68.1% may reflect pricing power or favorable mix.
JNJ — Strengths
Strengths for Johnson & Johnson (JNJ) inferred from public financial metrics:
- Revenue growth of 6.6% year-over-year.
- Return on equity near 25.7% — efficient use of shareholder capital.
- Gross margin of 68.1% supports competitive unit economics.
- Positive free cash flow ($16.89B).
- Dividend yield of 2.0% for income-oriented holders.
- Moderate leverage (debt/equity 57.71).
JNJ — Weaknesses
Weaknesses and pressure points for Johnson & Johnson (JNJ) based on available data:
- Earnings decline of -0.9% year-over-year.
JNJ — Opportunities
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
JNJ — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
JNJ — Summary
Johnson & Johnson (JNJ) is a mega-cap Healthcare company focused on Drug Manufacturers - General, listed on NYQ. Last price $269.17 with market cap $648.67B. Trailing P/E 31.26×. Revenue grew 6.6% year-over-year per public data. Notable strengths include revenue growth of 6.6% year-over-year. Key watch items include earnings decline of -0.9% year-over-year. Review free estimates and earnings pages for JNJ; upgrade for institutional ownership and live headlines.
Start Free — open JNJ in Vest Terminal
Access live data, filings, ownership, and analysis for Johnson & Johnson.
Johnson & Johnson FAQ
What does Johnson & Johnson (JNJ) do?
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers produc…
What is JNJ's P/E ratio?
Johnson & Johnson has a trailing P/E of 31.26× based on publicly available market data.
Does JNJ pay a dividend?
Indicated dividend yield: 2.0%. Confirm ex-dates and payout history in Vest Terminal.
What sector is JNJ in?
Johnson & Johnson is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is JNJ's market capitalization?
Approximate market cap: $648.67B.
What are the main risks for JNJ?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of JNJ?
Potential positives include revenue growth of 6.6% year-over-year, return on equity near 25.7% — efficient use of shareholder capital.
Where can I get analyst estimates for JNJ?
Public analyst price targets and consensus for Johnson & Johnson are on the free /stocks/jnj/estimates page. Deeper estimate history and models are available in Vest Terminal.